Nuvation Bio Inc. · NYSE:NUVB
Nuvation Bio — Investor Presentation (March 2021)
54 slides from Nuvation Bio's investor presentation, March 2021

Slide 1: Nuvation Bio March 2021
JPR ae Nuvation Bio A Aa y MARCH 2021

Slide 2: Forward Looking Statements and Disclaimers
FORWARD LOOKING STATEMENTS AND DISCLAIMERS Disclaimer: This presentation (“Presentation”) has been prepared to assist interested parties in making their own evaluation with respect to Nuvation Bio Inc. and for no other purpose. Neither the Securities and Exchange Commission nor any securities commis

Slide 3: Nuvation Bio Overview & Pipeline
Nuvation Bio Overview & Pipeline

Slide 4: Tackling the Greatest Unmet Needs in Oncology
TACKLING THE GREATEST UNMET NEEDS IN ONCOLOGY Experienced biotech leadership team led by David Hung, which successfully developed major oncology drugs including Xtandi ($3.7B in 2019 sales) and Talzenna Broad wholly-owned pipeline with strong IP protection First patient dosed with NUV-422 in P

Slide 5: Highly Experienced Management Team & Board
HIGHLY EXPERIENCED MANAGEMENT TEAM & BOARD LEADERSHIP TEAM SERGEY JENNIFER GARY LISA STACY David DAVID YURASOV, FOX HATTERSLEY, DeLUCA, Ph.D. MARKEL Hanley HUNG, M.D.* M.D., Ph.D. Chief Financial Officer Ph.D. SVP of Regulatory Affairs SVP of Human Resources Founder, President and Chief Technical Op

Slide 6: Deep Pipeline Targeting Multiple Oncology Indications
DEEP PIPELINE TARGETING MULTIPLE ONCOLOGY INDICATIONS Product Program Potential Indication(s) Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestones Candidate December 2020 First patient dosed in Phase 1/2 High- High-grade Glioma grade Glioma trial Brain metastases CDK 2/4/6 NUV-422 1H22 Initiat

Slide 7: NUV-422 | CDK 2/4/6
NUV-422 | CDK 2/4/6 Dec 2020 First High-grade Glioma patient dosed Brain Metastases 1H22 Initiate Ph1 trial ER+ mBC 2H22 Initiate Ph1 trial mCRPC 4Q22 Initiate Ph1 trial

Slide 8: CDK2 Drives Resistance to CDK4/6 Inhibitors
CDK2 DRIVES RESISTANCE TO CDK4/6 INHIBITORS TUMOR GROWTH SIGNALING CDK4/6 Inhibitors No Pharmacological Intervention Addressing Resistance Tumors respond to CDK4/6 inhibition by CDK4/6 CDK2 signaling through CDK2, driving resistance Selectively targeting TUMOR GROWTH SIGNALING In Presence of Fir

Slide 9: NUV-422 Is a Potent Inhibitor of CDK2/4/6 That Avoids CDK1
NUV-422 IS A POTENT INHIBITOR OF CDK2/4/6 THAT AVOIDS CDK1 DRIVES EFFICACY CAUSES TOXICITY 1st Generation CDK 4 CDK 6 CDK 2 CDK 1 2 2 10000 10000 4 2 2470 10000 2 10 504 1627 2nd Generation CDK 4 CDK 6 CDK 2 CDK 1 PF-06873600 2 4 0.3 2 NUV-422 2 1 7 73 IC50 (nM) NUV-422 has good Target selectivity

Slide 10: CDK2 Activity May Explain Discordant Results in Breast Cancer Trials
CDK2 ACTIVITY MAY EXPLAIN THE DISCORDANT RESULTS IN BREAST CANCER TRIALS BETWEEN FIRST-GENERATION CDK4/6 INHIBITORS IC50 (nM) (1) Metastatic CDK2 CDK4 CDK6 Adjuvant Setting Surgery & Radiation Monotherapy Label Adjuvant Therapy $25B PALLAS 2,470 4 2 PENELOPE-B 1L Metastatic $8B 504 2 10 monarch-E 2L

Slide 11: CDKN2A Deletion Commonly Drives Cancer Growth Through CDK2/4/6
CDKN2A DELETION OR ALTERATIONS COMMONLY DRIVE CANCER GROWTH THROUGH CDK2/4/6 (1) Surgery & Radiation Adjuvant Therapy $25B 1L Metastatic $8B 2L+ Metastatic Page | 11

Slide 12: CDKN2A Deletion and CDK2 Drive Growth of High-Grade Gliomas
CDKN2A DELETION (DRIVING CDK 2/4/6) AND CDK2 SPECIFICALLY DRIVES GROWTH OF PRIMARY HIGH-GRADE GLIOMAS Recent data from abemaciclib (Eli Lilly) in GBM patients supports targeting CDK2 may play an important role in controlling disease progression in HGG (1) Appay et al., 2020 (2) Wang et al., 2016 P

Slide 13: INSIGHT Phase 2 Trial of Abemaciclib in GBM
INSIGHT PHASE 2 TRIAL SHOWED THAT WHILE ABEMACICLIB IMPROVES PFS IN GBM PATIENTS, THIS EFFECT IS NOT DUE TO CDK4 ACTIVITY Abemaciclib (a potent inhibitor of CDK4/6 and a weak inhibitor of CDK2) demonstrated an improvement of progression-free survival (PFS) in newly diagnosed GBM patients in Phase 21

Slide 14: NUV-422 Superior to Temozolomide in Glioblastoma Xenograft Model
NUV-422 IS SUPERIOR TO STANDARD OF CARE TEMOZOLOMIDE IN IN VIVO XENOGRAFT MODEL OF GLIOBLASTOMA MULTIFORME Tumor Volume Vehicle Temozolomide 1 mg/kg NUV-422 10 mg/kg QD NUV-422 60 mg/kg QOD NUV-422 30 mg/kg QD NUV-422 60 mg/kg QD Page | 14

Slide 15: NUV-422 Achieves High Concentrations in the Brain
NUV-422 ACHIEVES HIGH CONCENTRATIONS IN THE BRAIN NUV-422 Concentration Six Hours Post Dose (Rat) Brain / Dose Brain Conc Plasma Conc Plasma (mg/kg) (nM) (nM) Ratio 30 4096 375 11 100 5827 506 12 12X Higher Exposure in Brain vs Plasma Page | 15

Slide 16: NUV-422-02: Seamless Phase 1/2 Trial Design in High Grade Gliomas
NUV-422-02: SEAMLESS PHASE 1/2 TRIAL DESIGN IN HIGH GRADE GLIOMAS Ph1 Dose-Escalation in Unselected Population Ph2 Dose Expansion in CDKN2A Deleted Patients Cohort…. n EXPANSION COHORT 1 CDKN2A deleted relapsed/refractory high-grade Select RP2D Cohort 4 glioma (up to 40 pts) with measurable disease

Slide 17: NUV-422 Active in Cell Lines of Cancers That Metastasize to Brain
BEYOND PRIMARY BRAIN TUMORS, NUV-422 IS ACTIVE IN MULTIPLE CELL LINES OF CANCERS WHICH COMMONLY METASTASIZE TO BRAIN Cell Proliferation (IC50 nM) Tumor Types with Brain Mets 2,000 Breast 1,750 Colon 1,500 1,250 NSCLC Renal Cancer 1,000 Lung Melanoma Melanoma cancer Leukemia 750 CDKN2A Deleted 500 So

Slide 18: CDK Inhibitors Dominate the ER+ Breast Treatment Landscape
CDK INHIBITORS DOMINATE THE ER+ BREAST TREATMENT LANDSCAPE ~500K Patients Annually Market Size Surgery & Radiation Positive Ph3 Data from MONARCH-E trial for Adjuvant Therapy $25B abemaciclib at ESMO20 suggests role for CDK4/6 inhibitors in adjuvant ER+ breast cancer 1L Metastatic $8B 2L+ Metastatic

Slide 19: NUV-422 Superior to Fulvestrant in ER+ Breast Cancer Xenograft Model
NUV-422 IS SUPERIOR TO STANDARD OF CARE FULVESTRANT IN IN VIVO XENOGRAFT MODEL OF ER+ METASTATIC BREAST CANCER Tumor Volume Page | 19

Slide 20: NUV-422 Deep Tumor Reductions in Enzalutamide-Resistant Prostate Model
NUV-422 CAUSES DEEP TUMOR REDUCTIONS IN AN ENZALUTAMIDE- RESISTANT PATIENT-DERIVED PROSTATE CANCER XENOGRAFT MODEL Tumor Volume (Day 39) Complete 40% 0% 0% 10% Responses Page | 20

Slide 21: Drug-Drug Conjugate (DDC) Platform
Drug-Drug Conjugate (DDC) Platform DDC1 [PARP-AR] mCRPC 2H22 Nominate First DDC2 [PARP-ER] Breast Cancer DDC Candidate DDC2 [PARP-ER] Ovarian Cancer

Slide 22: DDC Platform Is a Potential Advance Beyond ADCs
THE DRUG-DRUG CONJUGATE (DDC) PLATFORM IS A POTENTIALLY REVOLUTIONARY ADVANCE BEYOND ADCs Antibody Drug Conjugate Drug-Drug Conjugates Tissue-selective targeting improves therapeutic index vs. untargeted warhead Oral Antibody-Drug Binds intracellular and Conjugates cell membrane targets High

Slide 23: Drug-Drug Conjugates Designed to Bind Two Targets Simultaneously
DRUG-DRUG CONJUGATES ARE DESIGNED TO BIND TWO DIFFERENT TARGETS SIMULTANEOUSLY Drug Target X Drug X Drug Y Drug Target Y Fuse Binding Domains Drug Target X Drug X Drug Y Drug Target Y Page | 23

Slide 24: NUV-1156: Drug-Drug Conjugate Targeting AR and PARP
NUV-1156: A NOVEL NUVATION BIO DRUG-DRUG CONJUGATE THAT TARGETS AR AND PARP Two Separate Drugs / Two Separate Targets PARP Inhibitory AR Targeting Warhead Small Molecule PARP Lynparza Xtandi AR Fuse Binding Domains PARP Lynparza Xtandi AR Page | 24

Slide 25: NUV-1156 Targets High AR-Expressing Tissue Like Prostate Cancer
NUV-1156 TARGETS HIGH AR-EXPRESSING TISSUE LIKE PROSTATE CANCER AND AVOIDS LOW AR-EXPRESSING TISSUE LIKE BONE MARROW AND GI TRACT SCORE Androgen Receptor Expression Level High Medium Low Low AR expression in gut and bone marrow, the organs most affected by PARP toxicity Not Detected Small Intestines

Slide 26: NUV-1156 Kills Prostate Cancer Cells Resistant to Current Standards of Care
NUV-1156 DDC POTENTLY KILLS PROSTATE CANCER CELLS RESISTANT TO CURRENT STANDARDS OF CARE CELL PROLIFERATION IC50 (nM) IC50 (uM) >30,000 7844 + 6152 NUV-1156 201 (PARP-AR DDC) Page | 26

Slide 27: NUV-1156 Kills HR-Deficient and HR-Proficient Cancer Cell Lines
UNLIKE CURRENT PARP INHIBITORS, NUV-1156 KILLS HR-DEFICIENT AND HR-PROFICIENT CANCER CELL LINES WITH EQUALLY HIGH POTENCY NUV-1156 Prostate cancer TNBC TNBC TNBC HR-DEFICIENT (HRD) HR-PROFICIENT (HRP) 1/3 OF 2/3 OF TUMORS TUMORS >$7B IN 2025 PROJECTED SALES Page | 27

Slide 28: NUV-1156 Kills Enzalutamide-Resistant Prostate Cancer Cells, Spares Colon
NUV-1156 KILLS ENZALUTAMIDE-RESISTANT PROSTATE CANCER (HIGH AR) CELLS BUT SPARES HEALTHY COLON (LOW AR) CELLS IN VITRO APPROVED PARP INHIBITORS HAVE HIGH RATES OF GI TOXICITY (1) 0.3uM 22RV1 PROSTATE CELLS (CANCER CELLS) IEC-6 RAT GUT EPITHELIAL CELLS (HEALTHY CELLS) Source: Lynparza Label Page | 28

Slide 29: Only Potentially Curative Procedure for Prostate Cancer Is Surgery/Radiation
THE ONLY POTENTIALLY CURATIVE PROCEDURE FOR PROSTATE CANCER CURRENTLY IS SURGICAL PROSTATECTOMY/RADIATION ABLATION ~600K Men Annually $15B Market Opportunity Surgery & Radiation No Approved Therapies Androgen Deprivation Tx Combined Androgen Blockade Side Effects of Non-Metastatic CRPC Standard of C

Slide 30: Vision: Prostate Specific DDC as Pharmacological Prostatectomy
NUVATION BIO’S VISION: USE PROSTATE SPECIFIC DDC TO ACHIEVE A NERVE/BLOOD VESSEL-SPARING “PHARMACOLOGICAL PROSTATECTOMY” Minimal Cell Death in Healthy Nerves or Blood Vessels 100% NUV-1156 has the potential Surviving Cells of All Types 90% to kill prostate cancer cells 80% with unprecedented 70% s

Slide 31: ER Expression Limited to Female Sex Organs; Low in Gut and Marrow
ER PROTEIN EXPRESSION IS LIMITED TO FEMALE SEX ORGANS; LOW ER EXPRESSION IN SITES OF PARP-RELATED TOXICITY LIKE GUT AND MARROW SCORE High Estrogen Receptor Expression Level Medium Low Low ER expression in gut and bone marrow, the organs most affected by PARP toxicity Not Detected Small Intestines Sm

Slide 32: NUV-1176 ER-Targeted DDC Kills HR-D and HR-P ER+ Breast Cancer Cells
NUV-1176, AN ER-TARGETED DDC, POTENTLY KILLS BOTH HR-D AND HR-P ER+ BREAST CANCER CELLS WITHOUT KILLING HEALTHY COLON CELLS IEC6 HR Deficient HR Proficient NUV-1176 ER+, HER2+ Breast ER+ Breast cancer ER+ Breast cancer ER+ Breast cancer 0.3uM cancer ER+ BREAST CANCER CELLS HEALTHY COLON CELLS Page |

Slide 33: NUV-868 | BET
NUV-868 | BET AML/solid tumors 1H22 Initiate Ph1 trial

Slide 34: BET: Bromodomain and Extra-Terminal Motif Proteins
BET: BROMODOMAIN AND EXTRA-TERMINAL MOTIF PROTEINS BET are a family of proteins with two bromodomains (BD1 and BD2) BET proteins can induce the expression of a number of oncogenes, including MYC – an oncogene that cannot be targeted directly with a drug To date, BET inhibitors have largely foc

Slide 35: NUV-868 Is a Highly Selective BD2 vs BD1 Inhibitor
NUV-868 IS A HIGHLY SELECTIVE BD2 VS BD1 INHIBITOR BET inhibitors have historically targeted BD1 and BD2 non-selectively, causing BD1 BD2 GI toxicity and thrombocytopenia Selective BD2 vs BD1 inhibition can improve tolerability but has been difficult to achieve Selective BD2 inhibitors have th

Slide 36: NUV-868 Potent in Killing AML Cells in Xenograft Models
NUV-868 IS HIGHLY POTENT IN KILLING ACUTE MYELOID LEUKEMIA (AML) CELLS IN IN VIVO XENOGRAFT MODELS Kasumi-1 MV-4-11 NUV-868 demonstrates striking anti-tumor activity in two AML xenograft models Page | 36

Slide 37: BD2 Selectivity Reduces Gut Toxicity Seen With Other BET Inhibitors
HIGH SELECTIVITY FOR BD2 OVER BD1 SIGNIFICANTLY REDUCES THE GUT TOXICITY OBSERVED WITH OTHER BET INHIBITORS ABBV-075 (Dual BD1 / BD2) NUV-868 (BD2 Selective) Avoids GI Toxicity Vehicle ABBV-075 Vehicle NUV-868 30 mg/kg BID A non-selective inhibitor (ABBV-075) Treatment of mice for 10 days with B

Slide 38: NUV-868 Deep Tumor Reductions in Enzalutamide-Resistant Prostate Model
NUV-868 CAUSES DEEP TUMOR REDUCTIONS IN AN ENZALUTAMIDE- RESISTANT PATIENT-DERIVED PROSTATE CANCER XENOGRAFT MODEL Individual Animal Tumor Volume Page | 38

Slide 39: NUV-569 | WEE1
NUV-569 | WEE1 Pancreatic Cancer/other solid tumors 2H22 Initiate Ph1 trial

Slide 40: WEE1 Inhibitors Increase Efficacy of DNA-Damaging Therapies
WEE1 INHIBITORS INCREASE THE EFFICACY OF DNA-DAMAGING THERAPIES BY FORCING CANCERS TO REPLICATE BEFORE THEY CAN REPAIR THEIR DNA radiation Wee1 inhibitors force replicate bad DNA TUMOR CELL tumors to replicate DEATH damaged DNA before it can be repaired Tumors Activate Their Wee1 Replicating dam

Slide 41: Promise of Existing WEE1 Inhibitors Is Limited by Tolerability
THE PROMISE OF EXISTING WEE1 INHIBITORS IS LIMITED BY TOLERABILITY AZD1775, a third-party Wee1 inhibitor, has shown partial responses in Efficacy uterine serous carcinoma, ovarian and pancreatic cancer Ovarian Cancer(1) Uterine Serous Carcinoma(2) Pancreatic Cancer(3) • Combo with carboplatin • Mono

Slide 42: NUV-569's Potent and Selective Profile = Less Toxicity
NUV-569’S HIGHLY POTENT AND SELECTIVE PROFILE = LESS TOXICITY Compound Wee1 PLK1 IEC6 NUV-569 7 687 2362 AZD1775 4 15 251 IC50 (nM) PLK1 is a ubiquitous cell kinase that may be responsible for gut and bone marrow toxicity NUV-569 is highly potent against Wee1 but avoids PLK1 unlike AZD1775 10X

Slide 43: NUV-569 Increases In Vitro Killing of Pancreatic Cancer Cells
NUV-569 SIGNIFICANTLY INCREASES IN VITRO KILLING OF PANCREATIC CANCER CELLS BY CHEMO AND/OR RADIATION 100% NUV-569 shows strong 90% synergy with standard-of- 80% care gemcitabine and radiation 70% + NUV-569 K i l l i n g & Gem 60% In-vivo xenograft tumor models ongoing 50% + NUV-569 In additio

Slide 44: NUV-1182 | A2A receptor
NUV-1182 | A2A receptor Solid Tumors in Combo with IO 4Q22 Initiate Phase 1 trial

Slide 45: NUV-1182, an Adenosine A2A Receptor Inhibitor, Boosts Immune Function
NUV-1182, AN ADENOSINE A2A RECEPTOR INHIBITOR, BOOSTS IMMUNE FUNCTION NUV-1182 is focused on targeting the A2A adenosine receptor, which plays multiple critical roles in human physiology and pathophysiology including anti- cancer immunity. Accumulation of adenosine in the tumor microenvironment

Slide 46: NUV-1182 Potent and Selective A2A vs A1 Inhibitor
NUV-1182 IS A POTENT AND SELECTIVE A2A VS A1 ADENOSINE RECEPTOR INHIBITOR IC50 (nM) AZD4635 CPI444 AB928 NUV-121 NUV-191 NUV-1182 A2A binding 20 7.1 2.4 2.4 1.4 2.9 A1 binding 366 118 16 21 9.4 234 A2A Selectivity (A2A/A1) 18 16 7 9 7 81 A2A cAMP 1614 1007 70 607 311 441 (400 nM NECA) PPB 155/238 10

Slide 47: NUV-1182 Attractive PK Profile, Does Not Cross Blood-Brain Barrier
NUV-1182 HAS AN ATTRACTIVE PK PROFILE, WITH GOOD ORAL BIOAVAILABILITY AND DOES NOT EFFECTIVELY CROSS THE BLOOD-BRAIN BARRIER Mouse Single Dose Pharmacokinetics NUV-1182 PO Dose Cmax (nM) Tmax (h) AUCINF (nM*h) t1/2 (h) 50 mg/kg 17667 0.5 34211 1.41 200 mg/kg 50029 0.5 216670 1.74 Brain to plasma r

Slide 48: NUV-1182 Increases Anti-Tumor Activity of Checkpoint Inhibitors in Melanoma Model
NUV-1182 INCREASES THE ANTI-TUMOR ACTIVITY OF IMMUNE CHECKPOINT INHIBITORS IN AN IN VIVO MELANOMA XENOGRAFT MODEL Melanoma CDX Model B16F10 Page | 48

Slide 49: Financial Overview
Financial Overview

Slide 50: Financing History
FINANCING HISTORY Nuvation Bio was founded on March 20, 2018 by Dr. David Hung $275M raised in June 2019 in a Series A from high profile, experienced investors including Fidelity, Baupost, Omega, EcoR1, Altitude, Citadel, Boxer, etc. Merger with Panacea (EcoR1 sponsored SPAC) and $500M in conc

Slide 51: Upcoming Milestones & Summary
Upcoming Milestones & Summary

Slide 52: Upcoming Catalysts Across Multiple Programs
UPCOMING CATALYSTS ACROSS MULTIPLE PROGRAMS 4Q20 1H21 2H21 1H22 2H22 1H23 Initiate Ph1 in Initiate Initiate Present first Brain Ph1 in Ph1 in efficacy data from Dosed first patient metastases ER+ mBC mCRPC High-grade CDK2/4/6 in Ph1 High-grade Glioma trial Glioma trial Top-line Ph1 data from High-gr

Slide 53: Tackling the Greatest Unmet Needs in Oncology
TACKLING THE GREATEST UNMET NEEDS IN ONCOLOGY Broad wholly-owned pipeline with strong IP protection Up to 5 INDs in 6 years Multiple drug lead candidates addressing large markets with blockbuster drug sales potential Leveraging and improving upon validated drug mechanisms Focused on best-i

Slide 54: Nuvation Bio February 2021
JPR ae Nuvation Bio A Aa y FEBRUARY 2021
Source: Internet Archive copy of s27.q4cdn.com
More decks from Nuvation Bio Inc.
Q2 2026 Earnings Presentation34 slides · Aug 6, 2026
Q1 2026 Earnings Presentation34 slides · May 4, 2026
Investor Presentation (January 2026)37 slides · January 2026
Investor Presentation (November 2025)36 slides · Nov 26, 2025
Investor Presentation (November 2025)39 slides · Nov 17, 2025
Q2 2025 Earnings Presentation6 slides · Aug 7, 2025